Comparative Pharmacology
Head-to-head clinical analysis: AZILSARTAN MEDOXOMIL versus BENICAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZILSARTAN MEDOXOMIL versus BENICAR.
AZILSARTAN MEDOXOMIL vs BENICAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angiotensin II receptor blocker (ARB) that selectively inhibits angiotensin II binding to AT1 receptors, reducing vasoconstriction, aldosterone secretion, and sympathetic activity.
Olmesartan medoxomil is a prodrug that is hydrolyzed to olmesartan, a selective angiotensin II receptor type 1 (AT1) antagonist. It blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II, reducing blood pressure.
40 mg orally once daily. May increase to 80 mg once daily if needed.
Initial: 20 mg orally once daily; titrate to 40 mg once daily. Maximum 40 mg/day.
None Documented
None Documented
Terminal half-life approximately 11 hours; supports once-daily dosing with sustained antihypertensive effect over 24 hours.
Clinical Note
moderateAzilsartan medoxomil + Benzydamine
"The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Benzydamine."
Clinical Note
moderateAzilsartan medoxomil + Droxicam
"The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Droxicam."
Clinical Note
moderateAzilsartan medoxomil + Loxoprofen
"The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Loxoprofen."
Clinical Note
moderateTerminal elimination half-life is approximately 13–15 hours after multiple dosing, supporting once-daily dosing.
Biliary/fecal (55% unchanged), renal (42% as inactive metabolites, <1% unchanged)
Olmesartan is excreted primarily in feces (approximately 50–65%) via biliary elimination, with about 35–50% eliminated renally in urine as unchanged drug.
Category C
Category C
Angiotensin II Receptor Blocker
Angiotensin II Receptor Blocker
Azilsartan medoxomil + Clonixin
"The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Clonixin."